KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$204.0 million.

  • Novavax's Cash from Investing Activities fell 527.83% to -$136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year increase of 112.67%. This contributed to the annual value of -$204.0 million for FY2024, which is 246.97% down from last year.
  • Novavax's Cash from Investing Activities amounted to -$204.0 million in FY2024, which was down 246.97% from -$58.8 million recorded in FY2023.
  • Novavax's Cash from Investing Activities' 5-year high stood at $100.2 million during FY2021, with a 5-year trough of -$377.8 million in FY2020.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$93.0 million (2022), whereas its average is -$118.6 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 1,081.45% in 2020, then soared by 126.51% in 2021.
  • Over the past 5 years, Novavax's Cash from Investing Activities (Yearly) stood at -$377.8 million in 2020, then spiked by 126.51% to $100.2 million in 2021, then slumped by 192.84% to -$93.0 million in 2022, then surged by 36.76% to -$58.8 million in 2023, then slumped by 246.97% to -$204.0 million in 2024.